Graph Therapeutics announced that it has raised $5 million in new funding, bringing its total funding to date to over $10 million, including non-dilutive funding. The new investment will support the advancement of the company’s therapeutics programs in inflammation and immunology.
The new funding includes participation from Daphni, the Paris-based venture capital firm, which has joined Graph’s investor syndicate. Existing investors SquareOne, Merantix Capital, and NAVEC Investment Management also continued their participation, with additional non-dilutive grant funding provided by the Austrian Research Promotion Agency and Austria Wirtschaftsservice.
Graph is advancing internal drug discovery programs across multiple inflammatory and immune-mediated disease indications. The company said its work is powered by platform infrastructure that has been substantially de-risked and validated across clinically relevant biological models.
The maturity of Graph’s platform also positions the company to pursue strategic out-licensing opportunities and partnerships. This approach is intended to translate platform validation into value beyond the company’s internal pipeline.
Graph’s platform combines live patient cell models with advanced machine learning to decode complex immune dysfunction. Building on the founding team’s experience in AI-driven precision oncology at Allcyte, which was acquired by Exscientia, Graph applies a lab-in-the-loop perturbation approach to primary patient cell samples and multi-omics data to identify disease mechanisms, drug targets, and biomarkers for immune-mediated diseases.
The company’s total funding to date includes non-dilutive grant awards from Austria’s innovation agencies, including the Austrian Research Promotion Agency’s Austrian Life Sciences program and the Austria Wirtschaftsservice Deep Tech Life Sciences Seed Financing program. Graph said these awards reflect independent validation of its scientific approach and Austria’s public funding ecosystem for deep tech life sciences companies.
KEY QUOTES:
“Graph’s platform has reached a critical inflection point as we are now generating actionable biological insights that directly inform our own drug discovery programs. Daphni’s conviction in our approach is a powerful signal as we begin to scale investment into asset programs. With their support alongside our existing investors, we have both the backing and the urgency to pursue precision medicines in I&I, and to show the industry that rigorously decoding immune dysfunction in real patient cells reveals what actually drives disease.”
Gregory Vladimer, PhD, Co-Founder and CEO of Graph Therapeutics
“Graph exemplifies the next generation of techbio: a company where deep technological innovation is inseparable from rigorous R&D, led by a team with a proven track record in precision medicine. The complexity of immune-mediated diseases demands exactly this kind of integrated approach, and we are excited to support the GraphTx team as they move into therapeutics.”
Sofia Dahoune, Partner at Daphni
